{"DataElement":{"publicId":"5633341","version":"1","preferredName":"Intervention or Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response for questions to determine patient eligibility for clinical trial participation as outlined in the protocol related to any activity that produces an effect, or that is intended to alter the course of a disease in a patient or population.","longName":"IVNPR_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5633340","version":"1","preferredName":"Intervention or Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233215v1.0:2494487v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233215","version":"1","preferredName":"Procedure","preferredDefinition":"A particular course of action intended to achieve a result.","longName":"C25218","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intervention or Procedure","conceptCode":"C25218","definition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9313AE8-B7EE-4260-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"ONEDATA","dateModified":"2005-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2494487","version":"1","preferredName":"Clinical Trial Eligibility Criteria","preferredDefinition":"Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17D7DFE2-3794-35DA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-05","modifiedBy":"ONEDATA","dateModified":"2006-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46E08C38-9C0A-6F84-E053-F662850AB013","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeDescription":"1/24/17 tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]}],"AlternateNames":[{"name":"PLN_STRT_AGNT_IND","type":"OID, NRG","context":"NRG"}],"ReferenceDocuments":[{"name":"Is patient receiving on going","type":"Preferred Question Text","description":"Is patient receiving on going radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic therapy directed at the tumor?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient received prior chemotherapy or radiotherapy including complementary and alternative medicine treatments (CAMs) within 4 weeks prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has baseline imaging been obtained within 30 days of Day 1 of study?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient received chemotherapy, radiotherapy or surgery less than or equal to 3 weeks prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Is patient receiving ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, immunotherapy, or biologic therapy, including investigational agents for their disease?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Have at least 21 days elapsed from prior therapy (chemotherapy or radiation)?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is patient receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (i.e. megestrol acetate, bisphosphonates)?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Will patient be receiving other anticancer-therapy (chemotherapy, immunotherapy, hormonal anti-cancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent while receiving study medication?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Have at least 21 days elapsed from prior systemic therapy (chemotherapy or radiation)?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"For subject with glioma was prior surgery (biopsy allowed) or radiation therapy more than 30 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient received systemic cytotoxic chemotherapy, immunotherapy for 2 weeks or other investigational agents for 3 weeks, or oral targeted agent for at least 4 half-lives, or radiotherapy to a non-brain site for 2 weeks before initiation of IPdR therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"For subject with glioma was prior surgery (biopsy allowed) or radiation therapy within three weeks prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has the patient received any prior cytotoxic therapy, immunotherapy, major surgery, anti-tumor vaccines or monoclonal antibodies in the 4 weeks or 5 half-lives, whichever is shorter, prior to C1D1?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient received prior chemotherapy, immunotherapy or investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or palliative radiotherapy within 2 weeks prior to first dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient received more than 2 lines of palliative systemic therapy (platinum-, taxane- or cetuximab-based chemotherapy or immunotherapy)?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient received chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient received any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Has patient received standard chemotherapy within 1 week of administration of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Is patient receiving, during screening and treatment phase of this trial, antineoplastic systemic chemotherapy. biological therapy or radiation therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Is patient receiving concurrent chemotherapy, radiation therapy or immunotherapy for AML/MDS?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient require the concurrent use of chemotherapy, interferon, zidovudine, arsenic, radiation therapy, or other specific anti-tumor therapy, during the course of this study?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Will patient be receiving any other anti-cancer therapy (chemotherapy, immunotherapy, hormonal anticancer therapy, radiotherapy), biological therapy or other novel agent while the patient is receiving study medication?     ","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has a Vertebroplasty and/or kyphoplasty, been performed at least 1 week prior to starting KRT-232 (AMG 232) + KRd?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Has patient received chemotherapy or radiotherapy within 3 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Has patient received small molecule targeted drug within 21 days or 5 half-lives, whichever is shorter prior to initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"If patient is under the age of majority, will patient be undergoing a procedure that is scheduled due to medical necessity?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is patient receiving chloroquine/hydroxychloroquine?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient received any systemic chemotherapy or radiotherapy within 3 weeks prior to study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"For Phase 2 only: Has patient had no more than one intervening therapy since progression on BRAF/MEK inhibitor therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Has patient had major surgery or radiotherapy within 14 days (or 7 days if radiotherapy field is small) prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"For patients undergoing leukapheresis: Prior to leukapheresis have at least 3 weeks elapsed since myelosuppresive chemotherapy or at least 6 weeks if prior nitrosourea?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Has patient received chemotherapy, immune checkpoint inhibitors, or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Is patient a candidate for concurrent, definitive cisplatin and radiation therapy as judged by the treating physician?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Has patient received prior chemotherapy, investigational agents, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Has patient had any of the following: major surgery or radiation within 4 weeks; palliative stereotactic radiation within 2 weeks; small-molecule targeted agents within 2 weeks or five half-lives, whichever is longer; chemotherapy otherwise not specified (including, but not limited to cytotoxic chemotherapy, antibody drug conjugates, retinoid therapy, hormonal therapy) within 3 weeks; immunotherapy or monoclonal antibody within 4 weeks; and nitrosoureas or mitomycin C within 6 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Was prior treatment with any chemotherapy or other investigational therapy including hormonal, biological, or targeted agents greater than 4 weeks (6 weeks for nitrosoureas or mitomycin C); or at least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Will patient require CYP3A4 modulating agents at any time during the study?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"If patient is receiving any medications or substances known to affect or with the potential to affect the activity of CBX-12 or exatecan, has eligibility been determined following review by the Principal Investigator?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Has the patient started an oral anti-cancer agent in the past 4 weeks or are they planning to start a new course of an oral anti-cancer agent, other than sex hormone inhibitors, within 4 weeks after registration?","url":null,"context":"NRG"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Is patient taking a substrate of MATE1 or MATE2K transporter (including metformin, acyclovir, estrone sulfate, ciprofloxacin and cephalexin)?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 2","type":"Alternate Question Text","description":"Has the patient started oral anti-cancer agent other than sex hormone inhibitors within the past 4 weeks?","url":null,"context":"NRG"},{"name":"NRG CRF Text 3","type":"Alternate Question Text","description":"Is the patient planning to start a new course of an oral anti-cancer agent other than sex hormone inhibitors, within 4 weeks after registration?","url":null,"context":"NRG"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46E161FD-E2EE-6F78-E053-F662850AA799","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeDescription":"1/24/17 tt  10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}